Presentation title Subtitle if needed
CEPI: A New Approach to Vaccine Funding and Innovation for Emerging Diseases Amy Finan CEO, Sabin Vaccine Institute
Overview of CEPI What is CEPI? •
CEPI is a partnership of public, private, philanthropic and civil society organisations
•
CEPI will stimulate, finance and coordinate vaccine development • against priority threats, • particularly when development is unlikely to occur through market incentives alone.
CEPI’s First Investors Investor Germany
Japan Norway Gates Foundation Wellcome Trust
European Commission* Australia Belgium
$540 million over 5 years + co-funding
Overview of CEPI How will CEPI work? •
CEPI will move vaccine candidates through late preclinical studies to proof of concept and safety in humans before epidemics begin • larger effectiveness trials can begin swiftly in an outbreak • small stockpiles are ready for potential emergency use
•
CEPI will build technical platforms and institutional capacities that can be rapidly deployed against new and unknown pathogens
CEPI’s end-to-end gap-filling role: a sustainable partnership approach CEPI facilitating
Significant focus by others
Phase Current Stakeholders
CEPI funding
Significant focus by others
1
2
3
4
Discovery
Development/ Licensure
Manufacturing
Delivery/ Stockpiling
Academia Governments WT/NIH EC/IMI GLOPID-R Industry Regulators Biotech
Industry Governments Regulators WT/NIH EC/IMI Bill & Melinda Gates Foundation BARDA/DTRA etc. WHO Biotech PDPs
Industry BARDA CMOs Regulators Governments WHO GHIF
Gavi UNICEF PAHO Governments WHO Industry Pandemic Emergency Facility (World Bank) WHO Contingency Fund
5
GAVI CREATED IN 2000: To accelerate coverage of available vaccines in the poorest counties Vaccine coverage in Gavi-supported countries by: 2020 2015 2000
Coverage refers to the final dose of each vaccine, unless otherwise stated. a Target population and coverage estimates are based on 32 yellow fever-endemic Gavi-supported countries in Africa. b Target population for HPV is 10 year old girls. Sources: WHO/UNICEF Estimates of National Immunization Coverage, 2016. 2020 coverage: Gavi strategic demand forecast version 12.
7
GAVI ACCOMPLISHMENTS SINCE 2000
Children immunized
Future deaths averted
580
>8
million
million
Stronger economies
>80
Sustainable future
9
billion US$
countries
costs averted related to illness
Have started to fully self-finance
8
CEPI’s end-to-end gap-filling role: a sustainable partnership approach CEPI facilitating
Significant focus by others
Phase Current Stakeholders
CEPI funding
Significant focus by others
1
2
3
4
Discovery
Development/ Licensure
Manufacturing
Delivery/ Stockpiling
Academia Governments WT/NIH EC/IMI GLOPID-R Industry Regulators Biotech
Industry Governments Regulators WT/NIH EC/IMI Bill & Melinda Gates Foundation BARDA/DTRA etc. WHO Biotech PDPs
Industry BARDA CMOs Regulators Governments WHO GHIF
Gavi UNICEF PAHO Governments WHO Industry Pandemic Emergency Facility (World Bank) WHO Contingency Fund
9
“A scientist who is also a human being cannot rest while knowledge which might be used to reduce suffering rests on the shelf.” Albert B. Sabin
10
Overview of CEPI What is CEPI? •
CEPI is a partnership of public, private, philanthropic and civil society organisations
•
CEPI will stimulate, finance and coordinate vaccine development • against priority threats, • particularly when development is unlikely to occur through market incentives alone.
CEPI’s First Investors Investor Germany
Japan Norway Gates Foundation Wellcome Trust
European Commission* Australia Belgium
$540 million over 5 years + co-funding
Overview of CEPI How will CEPI work? •
CEPI will move vaccine candidates through late preclinical studies to proof of concept and safety in humans before epidemics begin • larger effectiveness trials can begin swiftly in an outbreak • small stockpiles are ready for potential emergency use
•
CEPI will build technical platforms and institutional capacities that can be rapidly deployed against new and unknown pathogens
CEPI’s end-to-end gap-filling role: a sustainable partnership approach CEPI facilitating
Significant focus by others
Phase Current Stakeholders
CEPI funding
Significant focus by others
1
2
3
4
Discovery
Development/ Licensure
Manufacturing
Delivery/ Stockpiling
Academia Governments WT/NIH EC/IMI GLOPID-R Industry Regulators Biotech
Industry Governments Regulators WT/NIH EC/IMI Bill & Melinda Gates Foundation BARDA/DTRA etc. WHO Biotech PDPs
Industry BARDA CMOs Regulators Governments WHO GHIF
Gavi UNICEF PAHO Governments WHO Industry Pandemic Emergency Facility (World Bank) WHO Contingency Fund
5
GAVI CREATED IN 2000: To accelerate coverage of available vaccines in the poorest counties Vaccine coverage in Gavi-supported countries by: 2020 2015 2000
Coverage refers to the final dose of each vaccine, unless otherwise stated. a Target population and coverage estimates are based on 32 yellow fever-endemic Gavi-supported countries in Africa. b Target population for HPV is 10 year old girls. Sources: WHO/UNICEF Estimates of National Immunization Coverage, 2016. 2020 coverage: Gavi strategic demand forecast version 12.
7
GAVI ACCOMPLISHMENTS SINCE 2000
Children immunized
Future deaths averted
580
>8
million
million
Stronger economies
>80
Sustainable future
9
billion US$
countries
costs averted related to illness
Have started to fully self-finance
8
CEPI’s end-to-end gap-filling role: a sustainable partnership approach CEPI facilitating
Significant focus by others
Phase Current Stakeholders
CEPI funding
Significant focus by others
1
2
3
4
Discovery
Development/ Licensure
Manufacturing
Delivery/ Stockpiling
Academia Governments WT/NIH EC/IMI GLOPID-R Industry Regulators Biotech
Industry Governments Regulators WT/NIH EC/IMI Bill & Melinda Gates Foundation BARDA/DTRA etc. WHO Biotech PDPs
Industry BARDA CMOs Regulators Governments WHO GHIF
Gavi UNICEF PAHO Governments WHO Industry Pandemic Emergency Facility (World Bank) WHO Contingency Fund
9
“A scientist who is also a human being cannot rest while knowledge which might be used to reduce suffering rests on the shelf.” Albert B. Sabin
10
